Showing 1011-1020 of 18563 results for "".
Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs
https://reachmd.com/programs/cme/advancing-care-in-non-clear-cell-rcc-optimizing-ici-and-tkis/29872/Stay at the forefront of nccRCC care by exploring the latest advances in treatment strategies. Gain key insights into optimizing patient selection, enhancing diagnostic accuracy, and managing adverse events to improve patient outcomes. This comprehensive activity delves into emerging data, the ratioDiagnosing IBD: Is It IBD or Something Else? Can You Tell?
https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Patient Case Study: Targeting DED Inflammation
https://reachmd.com/programs/medical-industry-feature/patient-case-study-targeting-ded-inflammation/32270/Explore a case of dry eye disease (DED) with underlying inflammation and the potential role of XIIDRA® (lifitegrast ophthalmic solution) 5%.When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
https://reachmd.com/programs/video-library/when-to-start-using-sglt2i-in-hfref-initiating-guideline-recommended-treatment-options/14734/This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".Investigating Inflammatory Mediators in Chronic Rhinosinusitis
https://reachmd.com/programs/deep-breaths-updates-chest/investigating-inflammatory-mediators-chronic-rhinosinusitis/13423/Learn more about the role of inflammatory mediators in chronic rhinosinusitis.Difelikefalin: Managing CKD-aP for Improved Quality of Life
https://reachmd.com/clinical-practice/nephrology/difelikefalin-managing-ckd-ap-for-improved-quality-of-life/26641/Learn about the efficacy of difelikefalin in patients with CKD-aP, including real-world data from the European Managed Access Programme & the PARADIGM registry.Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
https://reachmd.com/programs/cme/tbd/37670/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.